BMS trials update: CheckMate-67T posts results; two studies added for irAE care and lung screening

Three Bristol-Myers Squibb-linked trials moved this week, ranging from a Phase 3 results posting to two newly listed studies.

• CheckMate-67T (NCT04810078), a Phase 3 trial comparing subcutaneous and intravenous nivolumab in previously treated advanced or metastatic clear cell renal cell carcinoma, posted results on 2026-09-22. The trial was designed to evaluate the drug levels, efficacy, safety, and tolerability of subcutaneous nivolumab versus intravenous nivolumab in participants with previously treated clear cell renal cell carcinoma that is advanced or has spread.¹ Enrollment was 681 participants (actual).¹
• The IRIS trial (NCT07836101), a Phase 2 study of sarilumab paired with immune checkpoint inhibitor rechallenge, is not yet recruiting, with an estimated start of 2026-10. Bristol-Myers Squibb is a collaborator; the lead sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The study will enroll patients with history of malignancy treated with immune checkpoint inhibitors that have developed a grade 2 or higher immune related adverse event requiring treatment discontinuation as deemed by the patient's treating physician.² Enrollment: 41 participants (estimated).²
• MAS-EXPAND (NCT07838519), an interventional screening study, is enrolling by invitation across seven VA medical centers. Bristol-Myers Squibb is a collaborator; the VA Office of Research and Development is the lead sponsor. This proof-of-concept, non-inferiority prospective cohort study aims to evaluate a personalized lung cancer screening protocol tailored to the Veteran population, enrolling 1,400 Veterans across seven VA medical centers.³